![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sagiment Biosciences Inc | NASDAQ:SGMT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.06 | -1.43% | 4.14 | 4.10 | 4.29 | 4.2301 | 4.00 | 4.16 | 303,728 | 01:00:00 |
Details of the presentation are as follows:
Abstract Title: Multicenter, randomized, double-blind, placebo-controlled trial of Fatty Acid Synthase (FASN) inhibitor, denifanstat, versus placebo in the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial.Abstract Number: 1300Presenter: Rohit Loomba, MD, MHScType: Oral presentationSession Title: NAFLD: TherapySession Date: Friday, June 23, 2023 Session Time: 8:30 a.m. CEST (2:30 a.m. ET)
For more information regarding EASL Congress 2023, please visit https://easl.eu/event/easl-congress-2023/.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic pathways in diseases such as NASH, certain cancers and acne. Sagimet compounds are designed to inhibit FASN, an enzyme involved in the production of fatty acids normally used for energy storage. In NASH, the activity of FASN enzyme is upregulated, resulting in excess accumulation of liver fat, inflammation and fibrosis. Sagimet’s lead product candidate, denifanstat, an oral, once-daily pill, is currently being tested in FASCINATE-2, a Phase 2b clinical trial in NASH with liver biopsy as the primary endpoint. In June 2020, Sagimet announced positive results from FASCINATE-1, its Phase 2 clinical trial for denifanstat. The results of the Phase 2 clinical trial were published in Gastroenterology, the official journal of the American Gastroenterological Association. For additional information about Sagimet Biosciences, please visit www.sagimet.com.
Contact:
Robert UhlManaging Director, ICR Westwicke858.356.5932robert.uhl@westwicke.com
1 Year Sagiment Biosciences Chart |
1 Month Sagiment Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions